Tagrisso 80 mg is an anti-cancer medication that belongs to the class of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI). It is used for the treatment of patients with non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor receptor (EGFR). The medication works by targeting cancer cells, preventing their growth and spread, thus contributing to improved treatment outcomes and enhanced effectiveness.
Indications for Use:
-
Treatment of non-small cell lung cancer (NSCLC) with positive EGFR mutations.
-
Used as a first-line treatment or after disease progression following prior therapies.
Mechanism of Action:
Tagrisso inhibits tyrosine kinase receptors in cancer cells carrying EGFR mutations, which blocks growth and proliferation signals and leads to the death of cancer cells.
Directions for Use:
Take one tablet (80 mg) orally once daily, with or without food, or as directed by a specialist physician.
Package Contents:
30 tablets
Product Specifications:
-
Strength: 80 mg
-
Type: Anti-cancer medication (EGFR-TKI)
-
To be taken under strict medical supervision
Warnings:
-
To be used by prescription only and under the supervision of an oncology specialist.
-
Keep out of reach of children.
-
Inform your physician about all medications and supplements you are taking before starting this treatment.
-
It is advised not to use this medication during pregnancy or breastfeeding unless recommended by a doctor.
Reviews
There are no reviews yet.